{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024174","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.409374+00:00","generated_at":"2026-05-16T18:38:58.159820+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M","bullets":["Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M","Cash $405K; working capital deficit $47.5M at Sep 30 vs $1.5M at Dec 31, 2024","Crown Medical appointed Special Counsel to recover $50M+ net A/R; first settlement completed","BE-Smart esophageal cancer test validated by Mayo Clinic; commercialization rollout underway","Nebula Genomics pro-forma profitable; strategic M&A discussions ongoing"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024174","json":"https://secwatch.observer/filing/0001493152-25-024174.json","markdown":"https://secwatch.observer/filing/0001493152-25-024174.md","text":"https://secwatch.observer/filing/0001493152-25-024174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/0001493152-25-024174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:38:58.159820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}